The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guideline update on the management of dyslipidemia continues to focus largely on how best to manage lipid levels to reduce cardiovascular (CV) risk. Although some things have remained the same, some important new recommendations have been added, based on evidence from several clinical trials published from 2019 onwards.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Dapagliflozin for T2D and heart failure
Epicardial fat reduced in patients with type 2 diabetes and HF
- A hub of biological aging
Mitochondrial dysfunction and energy metabolism
- Health Literacy
Promoting health literacy: from the abstract to the concrete level
- Pharmacological therapy
Anxiety symptoms in eating disorders
- Case study
Wiedemann-Steiner syndrome in a 2-year-old girl
- Chronic back pain
Care in the virtual hospital – the Back@home project
- Psoriatic arthritis
Long-term remission also possible without DMARDs
- Clinical relevance, benefits and limitations